- JSPR Dashboard
-
Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Jasper Therapeutics (JSPR) Financial statements
Company Profile
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | ||
---|---|---|---|---|---|---|
Total Revenue | ||||||
Cost of Revenue | ||||||
Gross Profit | ||||||
Gross Profit Margin (%) | ||||||
R&D Expense | ||||||
SG&A Expense | ||||||
Total Operating Expenses | ||||||
Operating Income or Loss | ||||||
Operating Margin (%) | ||||||
Interest Expense | ||||||
Total Other Income/Expenses | ||||||
Income Before Tax | ||||||
Income Tax Expense | ||||||
Income from Continuing Ops. | ||||||
Net Income | ||||||
Net Profit Margin (%) | ||||||
Net Income Available to Common Shareholders | ||||||
Basic EPS | ||||||
Diluted EPS | ||||||
Basic Average Shares | ||||||
Diluted Average Shares |
Sep 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | ||||||||||||||||||||
Cost of Revenue | ||||||||||||||||||||
Gross Profit | ||||||||||||||||||||
Gross Profit Margin (%) | ||||||||||||||||||||
R&D Expense | ||||||||||||||||||||
SG&A Expense | ||||||||||||||||||||
Total Operating Expenses | ||||||||||||||||||||
Operating Income or Loss | ||||||||||||||||||||
Operating Margin (%) | ||||||||||||||||||||
Interest Expense | ||||||||||||||||||||
Total Other Income/Expenses | ||||||||||||||||||||
Income Before Tax | ||||||||||||||||||||
Income Tax Expense | ||||||||||||||||||||
Income from Continuing Ops. | ||||||||||||||||||||
Net Income | ||||||||||||||||||||
Net Profit Margin (%) | ||||||||||||||||||||
Net Income Available to Common Shareholders | ||||||||||||||||||||
Basic EPS | ||||||||||||||||||||
Diluted EPS | ||||||||||||||||||||
Basic Average Shares | ||||||||||||||||||||
Diluted Average Shares |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | ||
---|---|---|---|---|---|---|
Current Assets | ||||||
Cash & Cash Equivalents | ||||||
Marketable Securities | ||||||
Receivables | ||||||
Inventories | ||||||
Other Current Assets | ||||||
Total Current Assets | ||||||
Non-Current Assets | ||||||
Marketable Securities | ||||||
PPE Net | ||||||
Intangibles inc. Goodwill | ||||||
Other Non-Current Assets | ||||||
Total Non-Current Assets | ||||||
Total Assets | ||||||
Current Liabilities | ||||||
Accounts Payable | ||||||
Deferred Revenues | ||||||
Debt, Current | ||||||
Accrued Liabilities | ||||||
Other Current Liabilities | ||||||
Total Current Liabilities | ||||||
Non-Current Liabilities | ||||||
Deferred Revenues | ||||||
Debt, Non-Current | ||||||
Other Non-Current Liabilities | ||||||
Total Non-Current Liabilities | ||||||
Total Liabilities | ||||||
Shareholders' Equity | ||||||
Common Stock | ||||||
Additional Paid-In Capital | ||||||
Retained Earnings | ||||||
Other Shareholders' Equity | ||||||
Total Shareholders' Equity | ||||||
Total Liabilities & Shareholders' Equity |
Sep 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Current Assets | ||||||||||||||||||||
Cash & Cash Equivalents | ||||||||||||||||||||
Marketable Securities | ||||||||||||||||||||
Receivables | ||||||||||||||||||||
Inventories | ||||||||||||||||||||
Other Current Assets | ||||||||||||||||||||
Total Current Assets | ||||||||||||||||||||
Non-Current Assets | ||||||||||||||||||||
Marketable Securities | ||||||||||||||||||||
PPE Net | ||||||||||||||||||||
Intangibles inc. Goodwill | ||||||||||||||||||||
Other Non-Current Assets | ||||||||||||||||||||
Total Non-Current Assets | ||||||||||||||||||||
Total Assets | ||||||||||||||||||||
Current Liabilities | ||||||||||||||||||||
Accounts Payable | ||||||||||||||||||||
Deferred Revenues | ||||||||||||||||||||
Debt, Current | ||||||||||||||||||||
Accrued Liabilities | ||||||||||||||||||||
Other Current Liabilities | ||||||||||||||||||||
Total Current Liabilities | ||||||||||||||||||||
Non-Current Liabilities | ||||||||||||||||||||
Deferred Revenues | ||||||||||||||||||||
Debt, Non-Current | ||||||||||||||||||||
Other Non-Current Liabilities | ||||||||||||||||||||
Total Non-Current Liabilities | ||||||||||||||||||||
Total Liabilities | ||||||||||||||||||||
Shareholders' Equity | ||||||||||||||||||||
Common Stock | ||||||||||||||||||||
Additional Paid-In Capital | ||||||||||||||||||||
Retained Earnings | ||||||||||||||||||||
Other Shareholders' Equity | ||||||||||||||||||||
Total Shareholders' Equity | ||||||||||||||||||||
Total Liabilities & Shareholders' Equity |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | ||
---|---|---|---|---|---|---|
Cash Flows from Operating Activities | ||||||
Net Income | ||||||
Depreciation & Amortization | ||||||
Deferred Income Taxes | ||||||
Stock Based Compensation | ||||||
Accounts Receivable | ||||||
Inventory | ||||||
Accounts Payable | ||||||
Deferred Revenue | ||||||
Other Non-Cash | ||||||
Operating Cash Flow | ||||||
Cash Flows from Investing Activities | ||||||
PPE Investments | ||||||
Net Acquisitions | ||||||
Purchase of Investments | ||||||
Sale of Investments | ||||||
Other Investing Activity | ||||||
Investing Cash Flow | ||||||
Cash Flows from Financing Activities | ||||||
Debt Issued | ||||||
Proceeds from Debt Repayment | ||||||
Debt Repayment | ||||||
Proceeds from Sale of Equity | ||||||
Equity Repurchased | ||||||
Dividend Paid | ||||||
Other Financing Activity | ||||||
Financing Cash Flow | ||||||
Cash Position | ||||||
Beginning Cash Position | ||||||
End Cash Position | ||||||
Change in Cash | ||||||
Free Cash Flow | ||||||
Operating Cash Flow | ||||||
Capital Expenditure | ||||||
Free Cash Flow |
Sep 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | ||||||||||||||||||||
Net Income | ||||||||||||||||||||
Depreciation & Amortization | ||||||||||||||||||||
Deferred Income Taxes | ||||||||||||||||||||
Stock Based Compensation | ||||||||||||||||||||
Accounts Receivable | ||||||||||||||||||||
Inventory | ||||||||||||||||||||
Accounts Payable | ||||||||||||||||||||
Deferred Revenue | ||||||||||||||||||||
Other Non-Cash | ||||||||||||||||||||
Operating Cash Flow | ||||||||||||||||||||
Cash Flows from Investing Activities | ||||||||||||||||||||
PPE Investments | ||||||||||||||||||||
Net Acquisitions | ||||||||||||||||||||
Purchase of Investments | ||||||||||||||||||||
Sale of Investments | ||||||||||||||||||||
Other Investing Activity | ||||||||||||||||||||
Investing Cash Flow | ||||||||||||||||||||
Cash Flows from Financing Activities | ||||||||||||||||||||
Debt Issued | ||||||||||||||||||||
Proceeds from Debt Repayment | ||||||||||||||||||||
Debt Repayment | ||||||||||||||||||||
Proceeds from Sale of Equity | ||||||||||||||||||||
Equity Repurchased | ||||||||||||||||||||
Dividend Paid | ||||||||||||||||||||
Other Financing Activity | ||||||||||||||||||||
Financing Cash Flow | ||||||||||||||||||||
Cash Position | ||||||||||||||||||||
Beginning Cash Position | ||||||||||||||||||||
End Cash Position | ||||||||||||||||||||
Change in Cash | ||||||||||||||||||||
Free Cash Flow | ||||||||||||||||||||
Operating Cash Flow | ||||||||||||||||||||
Capital Expenditure | ||||||||||||||||||||
Free Cash Flow |